Risks of clinical trial protocol amendments according to duration of the trial

Author:

Eleskina A. A.1ORCID,Pyatigorskaya N. V.1ORCID,Filippova O. V.1ORCID

Affiliation:

1. I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenovskiy University)

Abstract

Background. No clinical trial could be initiated and conducted without appropriate clinical trial protocol. Any change in information relating to patients’ safety and health during the trial must be recorded and approved by a form of amendment to the clinical trial protocol, which is a time-consuming and financially expensive process for the Sponsors of these studies.Goal. To analyze the probability of releasing of clinical trials protocols amendments and to determine the most "pregnable" period for their occurrence in the course of the trials.Materials and Methods. The results of clinical trial protocols analysis are presented, which were approved by Russian Health Authorities between three years from 2017 to 2019 inclusive. In total, 20 protocols and 39 amendments were analyzed. Results. In the first year of the study, 21 amendments were issued, representing slightly more than half (54%) of the total number of amendments. During the second year, 12 amendments were issued, (31%). For the third year of the trial, only 3 amendments (7%) were made and for the fourth — 4, which is 8% of the total.Conclusion. The largest number of protocol amendments came out at first two years of clinical trial. Thus, they are the most "dangerous" years in the life of a clinical study in connection with the examination of developed protocol in real life. These first two years show how carefully the protocol was designed, how it meets the requirements of regulatory authorities, criteria and recommendations of professional associations, how feasible and effective the various criteria and procedures are.

Publisher

Publishing House OKI

Subject

Applied Mathematics

Reference15 articles.

1. Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, Tugwell P. Developing core outcome sets for clinical trials: issues to consider. Trials. 2012 Aug 6;13:132. doi: 10.1186/1745-6215-13-132

2. Murashko MA, Parkhomenko DV, Asetskaya IL, et al. The role and practice of pharmacovigilance in Russian healthcare. Vestnik Roszdravnadzora. 2014;(3):182–90. (In Russ.).

3. FDA [Internet]. (In Russ.). URL: https://www.fda.gov/patients/drug-development-process/step-3-clinical-research#Clinical_Research_Phase_Studies (дата обращения: 20.11.2022).

4. Martin L, Hutchens M, Hawkins C, Radnov A. How much do clinical trials cost? Nat Rev Drug Discov. 2017 Jun;16(6):381–2. doi: 10.1038/nrd.2017.70

5. Tolmachev AV, Vostokova NV. Developing a registration study protocol. Remedium. Zhurnal o rossiiskom rynke lekarstv i meditsinskoi tekhnike. 2015;(4):54–7. (In Russ.).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3